Latest News
UCB and Biogen report additional positive Phase 3 data for investigational lupus treatment
9 November 2026 - Global biopharmaceutical company UCB (Euronext Brussels:UCB) and US biotechnology company Biogen Inc (NASDAQ:BIIB) on Monday announced additional clinical findings for dapirolizumab pegol (DZP), an investigational biologic for syste...
Valneva reports positive Phase 2 results for tetravalent Shigella vaccine candidate
9 November 2026 - French vaccine company Valneva SE (Nasdaq:VALN) (Euronext Paris:VLA) on Monday announced positive results from two Phase 2 trials of S4V2, its tetravalent bioconjugate vaccine candidate targeting shigellosis.The studies demonstrated...
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
9 November 2026 - French diagnostics company bioMérieux (Euronext Paris:BIM) announced on Monday that it has received US Food and Drug Administration (FDA) 510(k) clearance for its BIOFIRE FILMARRAY Gastrointestinal 1.1 (GI1.1) Panel and GI1.1...
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update
9 November 2026 - Diagnostic company Photocure ASA (OSE: PHO) confirmed on Monday that the anticipated Medicare coverage timeline for its AssureMDx bladder cancer test remains aligned with its original acquisition assumptions, following a newly publi...
RYBREVANT FASPRO co-formulated with Halozyme's ENHANZE technology approved by US FDA in advanced head and neck cancer
9 November 2026 - Biotechnology company Halozyme Therapeutics Inc (Nasdaq:HALO) announced on Friday that Johnson & Johnson (NYSE:JNJ) was granted accelerated approval from the US Food and Drug Administration (FDA) for RYBREVANT FASPRO (amivantama...